Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cct.2016.01.009 http://scihub22266oqcxt.onion/10.1016/j.cct.2016.01.009 C4818190!4818190!26825023     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Contemp+Clin+Trials 2016 ; 47 (ä): 217-27 Nephropedia Template TP {{tp|p=26825023|t=2016. Innovations for phase I dose-finding designs in pediatric oncology clinical trials |pdf=|usr=}}{{26825023}} gab.com Text Innovations for phase I dose-finding designs in pediatric oncology clinical trials JO: Contemp Clin Trials http://www.kidney.de/pget.php?&tw=1&pmid=26825023 #FOAvip Phase I oncology clinical trials are designed to identify the optimal dose that will be recommended for phase II trials. In pediatric oncology, the conduct of those trials raise specific challenges, as the disease is rare with limited therapeutic options. In addition, the tolerance profile is known from adult trials. This paper provides a review of the major recent developments in the design of these trials, inspired by the need to cope with the specific challenges of dose finding in cancer pediatric oncology. We reviewed simulation studies comparing designs dedicated to address these challenges. We also reviewed the design used in published dose-finding trials in pediatric oncology over the period 2009?2014. Three main fields of innovation were identified. First, designs that were developed in order to relax the rules for more flexible inclusions. Second, methods to incorporate data emerging from adult studies. Third, designs accounting for toxicity evaluation at repeated cycles in pediatric oncology. In addition to this overview, we propose some further directions for designing pediatric dose-finding trials. Twit Text FOAVip Innovations for phase I dose-finding designs in pediatric oncology clinical trials ????Contemp Clin Trials http://www.kidney.de/pget.php?&tw=1&pmid=26825023 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26825023 #FOAvip English Wikipedia <ref>{{Cite pmid|26825023}}</ref> Innovations for phase I dose-finding designs in pediatric oncology clinical trials #MMPMID26825023 Doussau A; Geoerger B; Jiménez I; Paoletti X Contemp Clin Trials 2016[Mar]; 47 (ä): 217-27 PMID26825023show ga Phase I oncology clinical trials are designed to identify the optimal dose that will be recommended for phase II trials. In pediatric oncology, the conduct of those trials raise specific challenges, as the disease is rare with limited therapeutic options. In addition, the tolerance profile is known from adult trials. This paper provides a review of the major recent developments in the design of these trials, inspired by the need to cope with the specific challenges of dose finding in cancer pediatric oncology. We reviewed simulation studies comparing designs dedicated to address these challenges. We also reviewed the design used in published dose-finding trials in pediatric oncology over the period 2009?2014. Three main fields of innovation were identified. First, designs that were developed in order to relax the rules for more flexible inclusions. Second, methods to incorporate data emerging from adult studies. Third, designs accounting for toxicity evaluation at repeated cycles in pediatric oncology. In addition to this overview, we propose some further directions for designing pediatric dose-finding trials. äInnovations for phase I dose-finding designs in pediatric oncology cli(epmc).pdf DeepDyve Pubget Overpricing